FAM46C as a Potential Marker for Pan-Cancer Prognosis and Predicting Immunotherapeutic Efficacy.

Front Genet · 2022 · PMC8864238 · PMID 35222533

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

However, a decreasing trend in the FAM46C expression levels was observed in patients with stage III–IV tumours such as THCA, liver hepatocellular carcinoma (LIHC), lung squamous carcinoma (LUSC), mesothelioma (MESO) and READ; however, the difference was not statistically significant ( Supplementary Figure 1 ).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.